GO:0001510 RNA methylation: Epitranscriptomic Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001510 RNA methylation describes the posttranscriptional addition of a methyl group to a nucleotide or 2'-O ribose in a polyribonucleotide, typically using S-adenosylmethionine as a cofactor.
• RNA methylation is a reversible epitranscriptomic mark that influences RNA stability, splicing, translation, and decay, and is implicated in inflammatory bowel disease, neurodevelopmental disorders, retrotransposon control, sepsis, and multiple cancers.
• Writers, erasers, and readers form the core regulatory machinery of RNA methylation, and their dysregulation is linked to breast cancer, hematologic malignancies, and mitochondrial dysfunction.
• DNA methyltransferase 1 (DNMT1) can bridge m5C RNA methylation to mitochondrial function, illustrating crosstalk between DNA and RNA methylation pathways.
• RNA methylation-related inhibitors are emerging as therapeutic candidates for cancer therapy, underscoring the druggability of this process.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are essential for dissecting causal roles of RNA methylation regulators in disease.
Description
RNA methylation (GO:0001510) is a biological process defined as the posttranscriptional addition of a methyl group to either a nucleotide or the 2'-O ribose of a polyribonucleotide, usually using S-adenosylmethionine as a cofactor. This process generates chemical marks such as N6-methyladenosine (m6A), 5-methylcytosine (m5C), and 7-methylguanosine (m7G) on RNA molecules, which collectively constitute a dynamic epitranscriptomic layer that regulates gene expression beyond the DNA sequence. Because these marks are reversible and can be installed, removed, and interpreted by dedicated proteins, RNA methylation sits at the interface of RNA biology, epigenetics, and disease. Researchers study GO:0001510 because it affects nearly every stage of the RNA life cycle, including splicing, export, stability, translation, and decay. Dysregulated RNA methylation has been linked to inflammatory bowel disease, neurodevelopmental disorders, retrotransposon control, sepsis, breast cancer, and hematologic malignancies. The clinical relevance of this process is further highlighted by the emergence of RNA methylation-related inhibitors as potential cancer therapeutics. Mechanistically, RNA methylation depends on writer enzymes that deposit methyl groups, eraser enzymes that remove them, and reader proteins that recognize the marks and translate them into functional outcomes. This writer-eraser-reader framework provides a conceptual roadmap for experimental interrogation using CRISPR-based models, RNA sequencing, and epitranscriptomic profiling.
RNA methylation At A Glance
| GO ID | GO:0001510 |
|---|---|
| GO term | RNA methylation |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Definition | Posttranscriptional addition of a methyl group to either a nucleotide or 2'-O ribose in a polyribonucleotide; usually uses S-adenosylmethionine as a cofactor |
| Major function | Epitranscriptomic regulation of RNA stability, splicing, translation, and decay |
| Cofactor | S-adenosylmethionine (SAM) |
| Representative marks | m6A, m5C, m7G |
| Disease relevance | Inflammatory bowel disease, neurodevelopmental disorders, sepsis, breast cancer, hematologic malignancies |
What Is GO:0001510?
GO:0001510 RNA methylation is the posttranscriptional addition of a methyl group to either a nucleotide base or the 2'-O ribose of a polyribonucleotide. The reaction typically uses S-adenosylmethionine (SAM) as the methyl donor. This term encompasses methylation events on multiple RNA species and at multiple positions, including m6A, m5C, and m7G modifications, and represents a core mechanism of epitranscriptomic regulation.
Why Is RNA methylation Important in Cell Biology?
RNA methylation is important because it provides a reversible and dynamic layer of gene regulation that operates at the RNA level, influencing how transcripts are processed, translated, and degraded. This process is essential for normal development and cellular homeostasis, and its disruption is associated with a broad spectrum of human diseases, including inflammatory bowel disease, neurodevelopmental disorders, sepsis, breast cancer, and hematologic malignancies. The involvement of RNA methylation in retrotransposon control further underscores its role in genome stability. Because RNA methylation regulators are amenable to pharmacological inhibition, this process represents a promising therapeutic axis in oncology and beyond.
• RNA methylation regulates RNA stability, splicing, translation, and decay, making it a central node in posttranscriptional gene control.
• Dysregulated RNA methylation is implicated in inflammatory bowel disease, highlighting its role in immune and inflammatory pathways.
• RNA methylation is critical for neurodevelopment, and its disruption is linked to related neurological diseases.
• RNA methylation contributes to retrotransposon control, thereby supporting genome integrity.
• m5C RNA methylation can be modulated by DNMT1 and is connected to mitochondrial function.
• RNA methylation regulators are dysregulated in sepsis, suggesting roles in systemic inflammatory responses.
• RNA methylation-related inhibitors show therapeutic potential for cancer therapy.
• m6A, m7G, and m5C methylation patterns provide insights into breast cancer biology.
• RNA methylation is emerging as a relevant pathway in hematologic malignancies.
• CRISPR-based models enable causal testing of RNA methylation genes in disease contexts.
What Happens During RNA methylation?
Writer-mediated deposition of methyl marks
In simple terms: Writer enzymes act like molecular pens that add a small chemical tag called a methyl group onto RNA.
The first step in RNA methylation is the deposition of a methyl group onto a target nucleotide or 2'-O ribose by writer enzymes, typically using S-adenosylmethionine as the methyl donor. These writers include methyltransferases that generate marks such as m6A, m5C, and m7G on various RNA species. The specificity of writer enzymes determines which transcripts and which positions receive methylation, thereby shaping the epitranscriptomic landscape.
Reader-mediated interpretation of methyl marks
In simple terms: Reader proteins recognize the methyl tags and translate them into cellular actions.
Once deposited, RNA methylation marks are recognized by reader proteins that interpret the modification and recruit downstream machinery to influence RNA fate. Readers can affect RNA splicing, export, stability, translation, and decay, thereby converting a chemical mark into a functional outcome. The diversity of reader proteins allows a single methylation mark to have context-dependent effects.
Eraser-mediated removal and reversibility
In simple terms: Eraser enzymes can remove the methyl tags, making RNA methylation a reversible process.
RNA methylation is dynamic because eraser enzymes can remove methyl groups from RNA, reversing the modification. This reversibility allows cells to rapidly adjust RNA fate in response to developmental or environmental cues. The balance between writer and eraser activity determines the steady-state level of methylation on a given transcript.
Functional consequences for RNA metabolism
In simple terms: Methyl tags change how RNA molecules behave inside cells.
RNA methylation influences multiple steps of RNA metabolism, including splicing, nuclear export, translation efficiency, and transcript stability. These functional consequences are mediated by reader proteins and can affect the expression of key genes involved in inflammation, neurodevelopment, and cancer. Dysregulation of these steps contributes to disease phenotypes such as inflammatory bowel disease, neurodevelopmental disorders, and malignancies.
Crosstalk with other methylation pathways
In simple terms: RNA methylation can communicate with other cellular methylation systems.
Emerging evidence indicates crosstalk between RNA methylation and other methylation pathways, such as DNA methylation machinery. For example, DNA methyltransferase 1 (DNMT1) can modulate mitochondrial function through bridging m5C RNA methylation, illustrating how RNA methylation intersects with mitochondrial biology. Such crosstalk expands the functional reach of GO:0001510 beyond canonical RNA processing.
Key Genes Involved in GO:0001510 RNA methylation
The following genes and proteins represent core components of the RNA methylation machinery, including writers, erasers, readers, and associated factors implicated in disease and development.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL3 | m6A writer methyltransferase | Core m6A deposition; implicated in cancer and inflammatory pathways |
| METTL14 | m6A writer methyltransferase | Partners with METTL3 for m6A deposition; studied in cancer and development |
| WTAP | m6A writer complex adaptor | Required for METTL3/METTL14 complex localization and function |
| FTO | m6A/m6Am eraser demethylase | Reverses methylation; linked to neurodevelopment and cancer |
| ALKBH5 | m6A eraser demethylase | Removes m6A; implicated in cancer and inflammation |
| YTHDF1 | m6A reader | Promotes translation of methylated transcripts |
| YTHDF2 | m6A reader | Promotes decay of methylated transcripts |
| YTHDF3 | m6A reader | Modulates translation and decay of m6A RNAs |
| IGF2BP1 | m6A reader | Enhances stability of methylated transcripts |
| NSUN2 | m5C writer methyltransferase | Deposits m5C on RNA; linked to cancer and neurodevelopment |
| DNMT1 | DNA methyltransferase with RNA methylation crosstalk | Bridges m5C RNA methylation to mitochondrial function |
| ALYREF | m5C reader | Recognizes m5C and influences RNA export |
| METTL1 | m7G writer methyltransferase | Deposits m7G on RNA; implicated in cancer |
| WTAP | Writer complex component | Essential for m6A machinery assembly |
| VIRMA | m6A writer complex component | Contributes to m6A deposition specificity |
| ZC3H13 | m6A writer complex component | Regulates m6A machinery localization |
| RBM15 | m6A writer complex component | Facilitates m6A deposition on specific transcripts |
How Is RNA methylation Regulated?
RNA methylation is regulated by the coordinated activities of writer, eraser, and reader proteins, whose expression and localization determine the dynamic state of methyl marks on RNA. The process can be influenced by cellular signaling and metabolic states, and crosstalk with DNA methylation machinery has been demonstrated through DNMT1-mediated modulation of m5C RNA methylation and mitochondrial function. In disease contexts such as inflammatory bowel disease, sepsis, and cancer, altered expression of RNA methylation regulators contributes to pathological outcomes. The reversibility of RNA methylation allows for rapid regulatory adjustments in response to developmental and environmental cues.
RNA methylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL3 | Breast cancer, inflammatory pathways | Knockout and overexpression in breast cancer cell lines |
| FTO | Neurodevelopmental disorders | Point-mutation and knockout models in neuronal cells |
| ALKBH5 | Cancer and inflammation | Knockout models in cancer cell lines |
| DNMT1 | Mitochondrial dysfunction | Knockout and knock-in models to study m5C crosstalk |
| NSUN2 | Breast cancer, neurodevelopment | Knockout and overexpression models |
RNA methylation in inflammatory and immune disorders
RNA methylation has been implicated in inflammatory bowel disease, where dysregulated epitranscriptomic marks contribute to disease pathogenesis. In sepsis, RNA m6A methylation regulators are altered and associated with systemic inflammatory responses. These findings suggest that RNA methylation pathways may serve as biomarkers or therapeutic targets in inflammatory conditions.
RNA methylation in neurodevelopment and neurological disease
RNA methylation is essential for normal neurodevelopment, and its disruption is linked to related neurological diseases. Eraser enzymes such as FTO and reader proteins influence neuronal gene expression programs, and their dysregulation can contribute to neurodevelopmental pathology. This positions RNA methylation as a key process in developmental neuroscience.
RNA methylation in cancer
RNA methylation is extensively studied in cancer, including breast cancer and hematologic malignancies. m6A, m7G, and m5C modifications and their regulators influence tumor cell proliferation, survival, and metastasis. RNA methylation-related inhibitors have shown therapeutic potential for cancer therapy, highlighting the druggability of this pathway. In hematologic malignancies, RNA methylation is an emerging area of investigation with potential clinical implications.
RNA methylation in retrotransposon control and genome stability
RNA methylation contributes to retrotransposon control, thereby helping to maintain genome stability. This function connects RNA methylation to defense mechanisms against transposable element activity. Dysregulation of this process could have implications for genome integrity and disease.
From RNA methylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a writer gene affect RNA methylation levels? | CRISPR knockout of METTL3 or METTL14 |
| Does a specific point mutation in an eraser alter demethylase activity? | CRISPR point-mutation knock-in of FTO or ALKBH5 |
| Does overexpression of a reader promote tumor growth? | CRISPR overexpression of YTHDF1 or IGF2BP1 |
| Does a tagged writer protein localize to specific RNA transcripts? | Tagged knock-in of METTL3 |
| Does DNMT1-mediated m5C RNA methylation affect mitochondrial function? | Knockout and knock-in of DNMT1 |
| Does RNA methylation regulate retrotransposon silencing? | Knockout of writer or reader genes followed by retrotransposon assays |
How to Study the RNA methylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| MeRIP-seq | Transcriptome-wide m6A methylation sites | Mapping RNA methylation changes in disease |
| m6A-seq | m6A modification landscape | Comparing methylation patterns across conditions |
| Polysome profiling | Translation efficiency of methylated transcripts | Assessing reader protein function |
| RNA stability assay | Half-life of methylated transcripts | Linking methylation to RNA decay |
| Methyltransferase activity assay | Enzymatic activity of writer proteins | Validating writer function in vitro |
| CRISPR knockout | Loss-of-function phenotype | Testing causal roles of RNA methylation genes |
| CRISPR point mutation | Effect of specific amino acid changes | Dissecting catalytic residues in erasers/writers |
| Proteomics | Protein interaction networks | Identifying reader complexes |
Epitranscriptomic profiling by RNA sequencing
RNA sequencing-based methods such as MeRIP-seq and m6A-seq enable transcriptome-wide mapping of RNA methylation marks. These approaches identify which transcripts carry m6A, m5C, or m7G modifications and how these patterns change across conditions. They are foundational for studying GO:0001510 in disease models.
Functional assays for RNA stability and translation
Reporter assays and polysome profiling can measure how RNA methylation affects transcript stability and translation efficiency. These methods help link specific methylation marks to changes in protein output. They are particularly useful when studying reader proteins such as YTHDF1 and YTHDF2.
CRISPR-based genetic perturbation
CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of RNA methylation genes. These models can be used to determine whether a specific writer, eraser, or reader is required for a disease phenotype. They are also valuable for validating therapeutic targets.
Biochemical and proteomic approaches
Biochemical assays can measure methyltransferase activity and S-adenosylmethionine utilization in vitro. Proteomic approaches can identify reader protein complexes and interacting partners. These methods complement transcriptomic profiling to provide a mechanistic understanding of RNA methylation.
How CRISPR Can Be Used to Study GO:0001510 RNA methylation
Knockout
CRISPR knockout of RNA methylation writers, erasers, or readers can reveal their essential functions in RNA processing and disease phenotypes. For example, knocking out METTL3 or METTL14 reduces m6A levels and affects transcript stability and translation. Knockout models are widely used to test causal roles in cancer and inflammatory diseases.
Point Mutation
CRISPR point-mutation knock-in allows precise modification of catalytic residues in RNA methylation enzymes, enabling separation of enzymatic activity from scaffolding functions. This approach is particularly useful for studying erasers such as FTO and ALKBH5. Point-mutation models help define the mechanistic contribution of specific methylation events.
Knock-in
Knock-in of tagged or reporter alleles enables visualization and tracking of RNA methylation proteins in live cells. Tagged knock-in of writer proteins can reveal their localization and dynamics on RNA transcripts. Knock-in models are also used to introduce disease-associated mutations.
Overexpression
CRISPR-mediated overexpression of RNA methylation regulators can model gain-of-function states observed in cancer and other diseases. Overexpression of readers such as YTHDF1 or IGF2BP1 can promote tumor growth and alter transcript stability. These models complement knockout studies to provide a bidirectional view of gene function.
How EDITGENE Supports RNA methylation Research
Researchers studying RNA methylation-related genes often need to determine whether a candidate gene is causally involved in a specific disease or developmental process. CRISPR-based models provide a rigorous framework for such causal inference, enabling knockout, point-mutation, knock-in, and overexpression studies in relevant cell types. By combining these genetic tools with epitranscriptomic profiling, investigators can dissect the writer-eraser-reader circuitry that governs RNA methylation and its downstream effects.
Contact EDITGENE today to design your custom CRISPR model for RNA methylation research.
Frequently Asked Questions About RNA methylation
What is RNA methylation (GO:0001510)?
RNA methylation is the posttranscriptional addition of a methyl group to a nucleotide or 2'-O ribose in a polyribonucleotide, usually using S-adenosylmethionine as a cofactor.
What genes are involved in RNA methylation?
Key genes include writers such as METTL3, METTL14, and NSUN2; erasers such as FTO and ALKBH5; and readers such as YTHDF1, YTHDF2, and ALYREF.
What diseases are linked to RNA methylation?
RNA methylation has been linked to inflammatory bowel disease, neurodevelopmental disorders, sepsis, breast cancer, and hematologic malignancies.
How does RNA methylation regulate gene expression?
RNA methylation influences RNA splicing, stability, translation, and decay through writer, eraser, and reader proteins.
What is the role of m6A in RNA methylation?
m6A is a major RNA methylation mark that affects transcript fate and is implicated in cancer and inflammatory diseases.
Can RNA methylation be targeted therapeutically?
RNA methylation-related inhibitors have shown therapeutic potential for cancer therapy, suggesting that this pathway is druggable.
What is the difference between m6A, m5C, and m7G?
These are distinct RNA methylation marks deposited by different writer enzymes and recognized by different reader proteins.
How is RNA methylation studied experimentally?
Common methods include MeRIP-seq, m6A-seq, polysome profiling, and CRISPR-based genetic perturbation.
What is the role of DNMT1 in RNA methylation?
DNMT1 can modulate mitochondrial function through bridging m5C RNA methylation, illustrating crosstalk between DNA and RNA methylation.
How does RNA methylation control retrotransposons?
RNA methylation contributes to retrotransposon control, helping to maintain genome stability.
Conclusion
GO:0001510 RNA methylation is a fundamental epitranscriptomic process that regulates RNA fate and influences a wide range of human diseases, including inflammatory bowel disease, neurodevelopmental disorders, sepsis, breast cancer, and hematologic malignancies. The writer-eraser-reader framework provides a mechanistic basis for understanding how methylation marks are deposited, interpreted, and removed. As RNA methylation-related inhibitors advance toward therapeutic applications, CRISPR-based models will remain essential for causal validation of targets. Researchers can leverage EDITGENE's knockout, point-mutation, knock-in, overexpression, and library screening services to interrogate RNA methylation genes in disease-relevant contexts. Combining these genetic tools with epitranscriptomic profiling will accelerate the translation of RNA methylation biology into clinical benefit.
References
- 1. Ozato Y et al.. 2024. RNA methylation in inflammatory bowel disease.. Cancer Sci 115(3):723-733 PMID: 38263895
- 2. Xia W et al.. 2024. RNA methylation in neurodevelopment and related diseases.. Acta Biochim Biophys Sin (Shanghai) 56(12):1723-1732 PMID: 39344412
- 3. Barter B et al.. 2025. RNA methylation in retrotransposon control.. Trends Genet 41(7):556-558 PMID: 40404522
- 4. Wang J et al.. 2025. DNA methyltransferase 1 modulates mitochondrial function through bridging m(5)C RNA methylation.. Mol Cell 85(10):1999-2016.e11 PMID: 40328247
- 5. Zhu L et al.. 2024. RNA m6A methylation regulators in sepsis.. Mol Cell Biochem 479(9):2165-2180 PMID: 37659034
- 6. Chen H et al.. 2024. RNA methylation-related inhibitors: Biological basis and therapeutic potential for cancer therapy.. Clin Transl Med 14(4):e1644 PMID: 38572667
- 7. Dai Y et al.. 2024. RNA methylation and breast cancer: insights into m6A, m7G and m5C.. Mol Biol Rep 52(1):27 PMID: 39611867
- 8. Guirguis AA. 2025. RNA methylation: where to from here for hematologic malignancies?. Exp Hematol 143:104694 PMID: 39647657
